Bill Detail
H.R. 1328
Congress: 119
Title
Supply Chain Security and Growth Act of 2025
Summary
Supply Chain Security and Growth Act of 2025 This bill establishes a tax credit for qualified investments made in certain facilities that are located in a U.S. possession and manufacture drugs, pharmaceuticals, semiconductors, or certain other items, subject to limitations. The bill also increases the deemed-paid foreign tax credit for taxes paid to a U.S. possession. Specifically, under the bill, a taxpayer (other than a prohibited foreign entity) is allowed a tax credit for 40% of an investment in certain property that is placed into service during the tax year; integral to the operation of a critical supply chain facility; and constructed, reconstructed, or erected by the taxpayer, or property acquired for original used by the taxpayer. The bill defines critical supply chain facility as a facility that (1) manufactures active pharmaceutical ingredients, drugs, biologic products, medical countermeasures, medical diagnostic devices, semiconductors, semiconductor manufacturing equipment, aerospace equipment, or artificial nanomaterials; and (2) is located in Puerto Rico, Guam, American Samoa, the Northern Mariana Islands, or the Virgin Islands. Under the bill, the tax credit is transferable and may be claimed as a direct cash payment (i.e., elective payment). (Limitations apply.) Finally, the bill increases to 100% (from 80%) the deemed-paid foreign tax credit for income taxes paid or accrued by a controlled foreign corporation (CFC) to a U.S. possession. (Under current law, a U.S. shareholder of a CFC is allowed a tax credit for income taxes paid by a CFC on certain income attributable to the U.S. shareholder.)
Sponsor
Rep. Nicole Malliotakis [R-NY-11]
Status
Referred to the House Committee on Ways and Means.
Status as of Nov 17, 2026, 3:47 AM · synced 11h ago
Introduced
2025-02-13
Data source mode: cache
Bill Engagement
Supply Chain Security and Growth Act of 2025 This bill establishes a tax credit for qualified investments made in certain facilities that are located in a U.S. possession and ma…
Lobbyists on the case
These are cached disclosure mentions, not verified current representation or confirmed event attendance.
- Abbvie, Inc.1 filing · 5 lobs
- Dorcas Adekunle2026 Q1
- Daniel Bachner2026 Q1
Limited preview · paid intelligence
Keep the intelligence current—not just this one record.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.
Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.
SEE A FINISHED HEALTHCARE EXAMPLE
Three days of Hill visits. Two Medicare access questions.
A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.
Read the finished healthcare brief →After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.